Business
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant
About this update from Biofrontera Inc.
First Phase 3 PDT study in patients with sBCC in the United States . Primary and secondary endpoints all highly statistically significant p